{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"363.9","value":"1428.3"}]}],"title":"Baseline (N = 81)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"325.6","value":"1683.0"}]}],"title":"Cycle 2 Day 1 6-hour post dose (N = 69)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"327.9","value":"1751.8"}]}],"title":"End of treatment (N = 40)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"}],"units":"Participants"}],"description":"Descriptive statistics (absolute value and change from baseline as measured by ratio to baseline) for each best overall response category (CR, PR, SD, PD or combined) have been used to summarize the data from optional soluble c-Met ectodomain assays for crizotinib treated patients.","dispersionType":"Standard Deviation","groups":[{"description":"Overall assessment for complete response, partial response, stable disease, progressive disease and early death","id":"OG000","title":"Overall Values"}],"paramType":"MEAN","populationDescription":"The soluble biomarker-evaluable population includes patients from the SA population that received PF-02341066, who have an optional blood sample prior to dosing on Cycle 1 Day 1 and have at least 1 on-treatment soluble biomarker evaluation (Cycle 2 Day 1 and/or end of treatment).","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycle 1, 2 to 6 hours post-dose on Day 1 of Cycle 2, end of treatment (up to 112 weeks)","title":"Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}